MedPath

A Phase 2 Randomized Study of LY2541546 versus Placebo in Postmenopausal Women with Low Bone Mineral Density:An Evaluation of the Dose Response Relationship Using Bone Mineral Density

Phase 2
Completed
Conditions
Osteoporosis
Registration Number
JPRN-jRCT2080221242
Lead Sponsor
Eli Lilly Japan K.K.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
completed
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

Have low BMD, defined as a T-score for lumbar spine of between -3.5 and -2.0, inclusive, based on the local DXA report as interpreted by the investigator. The method of determining Tscore values will be based on regional standards. Three of 4 vertebrae, L1 through L4, must be evaluable for BMD scoring, as measure by DXA.

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath